Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text

Life Sciences, Immunology, Pathology +14

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations

Medicine, Immunology, Oncology +16

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Roberto Salgado, Carsten Denkert, Sandra Demaria et al. · Annals of Oncology · 2014 · 3.1K citations · Full text

Medicine, Immunology, Oncology +16

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Ignace Vergote, Claes G. Tropé, Frédéric Amant et al. · New England Journal of Medicine · 2010 · 2.5K citations · Full text

Medicine, Oncology, Surgery +17

Intraepithelial CD8 ⁺ tumor-infiltrating lymphocytes and a high CD8 ⁺ /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

Eiichi Sato, Sara H. Olson, Jiyoung Ahn et al. · Proceedings of the National Academy of Sciences · 2005 · 2.4K citations · Full text

Life Sciences, Immunology, Oncology +17